1. Home
  2. EDU vs CYTK Comparison

EDU vs CYTK Comparison

Compare EDU & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Oriental Education & Technology Group Inc.

EDU

New Oriental Education & Technology Group Inc.

HOLD

Current Price

$46.54

Market Cap

9.4B

Sector

Real Estate

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$70.25

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDU
CYTK
Founded
1993
1997
Country
China
United States
Employees
84111
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
10.4B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
EDU
CYTK
Price
$46.54
$70.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
19
Target Price
$62.80
$89.26
AVG Volume (30 Days)
622.8K
3.0M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
2.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$12.83
$7.37
Revenue Next Year
$11.16
$310.19
P/E Ratio
$24.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.62
$31.52
52 Week High
$64.97
$80.20

Technical Indicators

Market Signals
Indicator
EDU
CYTK
Relative Strength Index (RSI) 32.51 43.39
Support Level $45.91 $59.07
Resistance Level $60.61 $79.66
Average True Range (ATR) 1.07 2.57
MACD -0.17 -1.09
Stochastic Oscillator 8.64 3.13

Price Performance

Historical Comparison
EDU
CYTK

About EDU New Oriental Education & Technology Group Inc.

New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: